

## Template Capital Change Notice

Updated as at June 2023

Section 1: Issuer information		
Name of issuer	EROAD Limited	
NZX ticker code	ERD	
Class of financial product	Further issue of unquoted Performance Share Rights ( <i>PSRs</i> ), convertible to EROAD ordinary shares pursuant to the 2024 Grant ( <i>2024 Grant</i> ) under EROAD's Long Term Incentive Plan ( <i>Plan</i> ).	
ISIN (If unknown, check on NZX website)	NZERDE0001S5	
Currency	NZD	
Section 2: Capital change details		
Number issued/acquired/redeemed	892,092	
Nominal value (if any)	N/A	
Issue/acquisition/redemption price per security	N/A	
Nature of the payment (for example, cash or other consideration)	No consideration is payable for the PSRs have a set exercise price of \$0.	
Amount paid up (if not in full)	N/A	
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) <sup>1</sup>	39.1%	
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	The PSRs issued under the 2024 Grant comprise three tranches. First Tranche The first tranche of PSRs becomes exercisable on a participant remaining employed on 31 March 2026 and in certain other circumstances. Second Tranche The second tranche of PSRs becomes exercisable where EROAD's total shareholder return (TSR) calculated over a period ending after the release of its results for the year ended 31 March 2026 is at least greater than the 40th percentile of the constituents of the	

<sup>1</sup> The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

S&P/ASX All Technology Index
(XTX). The percentage of PSRs
that become eligible for exercise
will increase on a straight line
basis from 50% where
EROAD's TSR is equal to the
40th percentile of the
constituents of the XTX to 100%
where EROAD's TSR is equal
to or greater than the 60th
percentile of the constituents of
the XTX. If EROAD's TSR is
equal to or greater than the 80th
percentile, the percentage
eligible for vesting will increase
on a straight line basis up to
200% vesting at the 100th
percentile.
Third Trancho The third trancho

	Third Tranche The third tranche of PSRs becomes exercisable based on the absolute financial performance of EROAD, which is dependent on EROAD's revenue, EBIT and free cash flow assessed on EROAD's financial statements for each relevant year (being the years ending 31 March 2024, 31 March 2025 and 31 March 2026) compared to EROAD's 3 - year budget set at the beginning of the 2024 Grant, as well as EROAD's cumulative performance over that time . Between 85% and 130% of the PSRs may become exercisable depending on achievement. If performance is less than 85%, then no PSRs will vest. Share rights vest subject to the terms and conditions outlined in EROAD's Long Term Incentive Plan Rules. On vesting, PSRs entitle the holder to one ordinary share in EROAD for no cash payment, subject to adjustment in accordance with the plan rules, ranking equally with all other EROAD Limited ordinary shares. The PSRs have a set exercise price of \$0.
Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	Issue of 892,092 PSRs for the FY24 Grant under EROAD's Long Term Incentive Plan. Further background regarding EROAD's FY24 Remuneration



## Template

Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the	Updated as at June 2023 Framework and the Plan can be found in EROAD's Remuneration Report released to the NZX and ASX on 23 May 2024. Board resolution dated 30 June 2023. EROAD has a total of 3,174,754 PSR's on issue.
Class held as Treasury Stock after the issue/acquisition/redemption.	<ul> <li>This total includes this PSR issue, and PSRs issued in connection with the following grants:</li> <li>EROAD Share Retention Grant 97,087 PSRs</li> <li>EROAD Share Retention Grant 457,253 PSRs</li> <li>EROAD FY24 LTI Grant 1,450,911 PSRs</li> <li>EROAD Share Retention Grant 220,462 PSRs</li> <li>56,949 PSRs of the same class from the FY20 EROAD LTI Grant remain on issue.</li> <li>No PSRs or EROAD Limited ordinary shares are held as treasury stock.</li> </ul>
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	N/A
Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Directors' resolutions dated 30 June 2023. NZX Listing Rule 4.6.1
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	See above. Share Rights are not transferrable and do not entitle the holder to receive dividends or other distributions or vote in respect of EROAD ordinary shares although under the terms of the plan an additional number of shares will be issued on conversion of fully vested PSRs to reflect

	dividends paid on EROAD Limited shares prior to exercise. Any ordinary shares issued on the valid exercise of PSRs will rank equally with existing ordinary shares.	
Date of issue/acquisition/redemption <sup>2</sup>	3 October 2024	
Section 3: Authority for this announcement and contact person		
Name of person authorised to make this announcement	Eleanor Koningham	
Contact person for this announcement	Eleanor Koningham	
Contact phone number	+64 2102761650	
Contact email address	Eleanor.koningham@eroad.com	
Date of release through MAP	3 October 2024	

<sup>&</sup>lt;sup>2</sup> Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).